In English | En español
Questions About Cancer? 1-800-4-CANCER

Find News Releases

Search For:
Between these dates:

All News Releases

Potential biological factor contributing to racial disparities in prostate cancer
NCI Cancer Center News
(Posted: 12/09/2013) - Researchers from the Medical University of South Carolina (home of the Hollings Cancer Center) have uncovered a potential biological factor that may contribute to disparities in prostate cancer incidence and mortality between African-American and non-Hispanic white men in the United States, according to results presented at the Sixth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved, held Dec. 6-9. In the United States, African-American men are 1.5 times more likely to develop prostate cancer and more than twice as likely to die from the disease compared with non-Hispanic white men.

New studies demonstrate that modified T cells are effective in treating blood-borne cancers
NCI News Note
(Posted: 12/09/2013) - At the 2013 American Society of Hematology meeting in Dec. 2013, James Kochenderfer, M.D., NCI, presented findings from two clinical trials evaluating the use of genetically modified immune system T cells as cancer therapy. These reports represent important advances in the understanding of gene therapy for treatment of advanced blood-borne cancers.

Unlocking how brain cancer cells hide from drugs
NCI Cancer Center News
(Posted: 12/06/2013) - Researchers from UCLA’s Jonsson Comprehensive Cancer Center (JCCC) have discovered a biological mechanism that allows brain tumor cells to escape from the drugs designed to target them, resulting in drug resistance. The study was published in the December 5, 2013 online issue of Science.

Cancer mutation likely trigger of scleroderma
NCI Cancer Center News
(Posted: 12/06/2013) - Johns Hopkins scientists have found evidence that cancer triggers the autoimmune disease scleroderma, which causes thickening and hardening of the skin and widespread organ damage. A report on the discovery, published in the Dec. 5 issue of Science, also suggests that a normal immune system is critical for preventing the development of common types of cancer. Johns Hopkins is home to the Sidney Kimmel Cancer Center.

Fred Hutchinson Cancer Research Center study examines predicting ovarian cancer by counting tumor-attacking immune cells
NCI Cancer Center News
(Posted: 12/05/2013) - Scientists at Fred Hutchinson Cancer Research Center have developed a new method for counting a special class of cancer-fighting cells – called tumor-infiltrating T lymphocytes, or TILs – reliably, quickly and cheaply in patients with early stage and advanced ovarian cancer.

3-D mammography increases cancer detection and reduces call-back rates
NCI Cancer Center News
(Posted: 12/04/2013) - Compared to traditional mammography, 3D mammography—known as digital breast tomosynthesis—found 22 percent more breast cancers and led to fewer call backs in a large screening study at the Hospital of the University of Pennsylvania (HUP), researchers reported at the annual meeting of the Radiological Society of North America (RSNA). The University of Pennsylvania is home to the Abramson Cancer Center.

Predicting outcome for high-dose IL-2 therapy in cancer patients
NCI Cancer Center News
(Posted: 12/03/2013) - Reporting in the Journal of Clinical Investigation, researchers at M.D. Anderson Cancer Center performed an in depth analysis of Treg populations in melanoma patients undergoing HD IL-2 therapy. The authors identified a distinct population of Treg cells that expressed the inducible T cell costimulator (ICOS) that was highly proliferative following the first cycle of HD IL-2.

Blocking antioxidants in cancer cells reduces tumor growth in mice
NCI Cancer Center News
(Posted: 12/03/2013) - Many cancers have adapted to cope with high levels of immune system-produced free radicals, also referred to as reactive oxygen species, by overproducing antioxidant proteins. One of these proteins, superoxide dismutase 1 (SOD1), is overproduced in lung adenocarcinomas and has been implicated as a target for chemotherapy. In the Journal of Clinical Investigation, researchers from Northwestern University (home of the Robert H. Lurie Comprehensive Cancer Center) report the effects of a SOD1 pharmacological inhibitor on non-small-cell lung cancer (NSCLC) cells.

New drug cuts risk of deadly transplant side effect in half
NCI Cancer Center News
(Posted: 12/03/2013) - A new class of drugs reduced the risk of patients contracting a serious and often deadly side effect of lifesaving bone marrow transplant treatments, according to a study from researchers at the University of Michigan Comprehensive Cancer Center. The study, the first to test this treatment in people, combined the drug vorinostat with standard medications given after transplant, resulting in 22 percent of patients developing graft-vs.-host disease compared to 42 percent of patients who typically develop this condition with standard medications alone. Results of the study appear in The Lancet Oncology.

Cyclin D1 governs microRNA processing in breast cancer
NCI Cancer Center News
(Posted: 11/29/2013) - Cyclin D1, a protein that helps push a replicating cell through the cell cycle, also mediates the processing and generation of mature microRNA (miRNA), according to new research from the Kimmel Cancer Center at Thomas Jefferson University published November 29 in Nature Communications. The research suggests that a protein strongly implicated in human cancer also governs the non-protein-coding genome. The non-coding genome, previously referred to as junk DNA, makes up most of the human genome, and unlike the coding genome, varies greatly between species.

< Previous  21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41  Next >